薬剤にマッチしたオリゴペプチドエキシピエントによって可能になった高負荷ナノアグレガートの誘導的発見
Naxhije Berisha1,2,3,4, Atena Farahpour1,2,3,4,5, Maithreyi Ramakrishnan1,2,3,5
1Nanoscience Initiative, Advanced Science Research Center, CUNY Graduate Center, City University of New York, New York, NY 10031, USA.
まとめ
研究者はペプチド薬物ナノ粒子を開発し,最大98%の薬物負荷を達成し,白血病モデルにおける抗腫瘍有効性を大幅に高めました. これらの設計ペプチドは,効率的な薬物投与システムのための新しいアプローチを提供します.
科学分野:
- バイオマテリアル科学 バイオマテリアル科学
- ナノテクノロジー ナノテクノロジー
- 薬物の配達 薬物の配達
背景:
- ナノ粒子は薬剤の薬動性を高めますが,薬剤の負荷効率が低いことがよくあります.
- 既存の薬物集積ナノ粒子は高負荷を示していますが,効率的な共同組立のために特定の補助物質が必要です.
- ペプチドは,その多様な化学特性により,新しい補助物質を設計するための多用途かつ生物分解性のプラットフォームを提供します.
研究 の 目的:
- 高負荷薬ナノ粒子を作るための設計補助物質としてのペプチドを調査する.
- 主要な構造的特徴を調節することによって,既知の補助物質を模倣するペンタペプチド基板の設計とスクリーニング.
- 前臨床がんモデルにおけるペプチド薬ナノ粒子の有効性を評価する.
主な方法:
- 設計されたペンタペプチド・スキャフォールドは,芳香度,硬度,電荷が異なる.
- 184種類のペプチド薬剤の配列をスクリーニングし,様々な治療用荷物を運びました.
- ナノ粒子の形成メカニズムを解明するために,分子動力学シミュレーションと質量スペクトロメトリを活用しました.
- レスタウルチニブを含むペプチド薬剤の配列を,急性骨髄性白血病のモデルで試験した.
主要な成果:
- ペプチド・ドラッグ・ナノ粒子で最大98%の薬物負荷を達成しました.
- コア・シェル構造形成の原動力として,特定されたトリプトファン-薬物相互作用と,充電された残留溶媒への曝露を特定した.
- レスタウルチニブとペプチド薬ナノ粒子を用いた急性骨髄性白血病のモデルにおける抗腫瘍効果の強化が実証された.
結論:
- オリゴペプチドは,治療用貨物との効率的な共同組み立てのための補助物質として合理的に設計することができます.
- 抗腫瘍効果が向上した高負荷ナノ粒子は,ペプチド薬の配方を使用して達成できます.
- このアプローチは,先進的な薬物投与システムを開発するための有望な戦略です.
関連する概念動画
Drug Discovery: Overview
11.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.9K
Sign Test for Matched Pairs
427
The sign test for matched pairs offers a robust method for comparing two paired samples, often for the effects of an intervention in one of them. This method is very useful in situations where the underlying distribution of the data is unknown. The test compares two related samples—often pre- and post-treatment measurements on the same subjects—to determine if there are significant differences in their median values.
To conduct the sign test, we first calculate the differences in...
To conduct the sign test, we first calculate the differences in...
427
Peptide Bonds
83.5K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
83.5K
Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
189
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
189
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K


